Krystal Biotech (KRYS) Cash from Operations Growth (1y) (2017 - 2026)
Krystal Biotech (KRYS) Cash from Operations Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn | 356.73% |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn | 74.39% |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn | 3.23% |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn | 158.60% |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | - |
| 10 | Krystal Biotech | 10.37 Bn | 9.54 Bn | 110.08 Mn | 159.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 159.56% |
| Dec 31, 2025 | 46.68% |
| Sep 30, 2025 | -32.62% |
| Jun 30, 2025 | 1,365.09% |
| Mar 31, 2025 | 94.92% |
| Dec 31, 2024 | 830.68% |
| Sep 30, 2024 | 377.29% |
| Jun 30, 2024 | 87.81% |
| Mar 31, 2024 | 160.74% |
| Dec 31, 2023 | 67.61% |
| Sep 30, 2023 | -7.81% |
| Jun 30, 2023 | 20.60% |
| Mar 31, 2023 | -68.82% |
| Dec 31, 2022 | -6.84% |
| Sep 30, 2022 | -171.37% |
| Jun 30, 2022 | -325.11% |
| Mar 31, 2022 | -60.48% |
| Dec 31, 2021 | -160.47% |
| Sep 30, 2021 | -7.04% |
| Jun 30, 2021 | -100.42% |